• +1-646-491-9876
    • +91-20-67278686

    Search

    Down Syndrome - Pipeline Review, H1 2017

    Down Syndrome - Pipeline Review, H1 2017

    • Report Code ID: RW0001689402
    • Category Healthcare
    • No. of Pages 65
    • Publication Month Feb-17
    • Publisher Name Global Markets Direct
    Report Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Down Syndrome - Pipeline Review, H1 2017, provides an overview of the Down Syndrome (Genetic Disorders) pipeline landscape.

    Down syndrome is a genetic disorder that causes lifelong mental retardation, developmental delays and other problems. Down syndrome varies in severity, so developmental problems range from moderate to serious. Children with Down syndrome have a distinct facial appearance. Though not all children with Down syndrome have the same features, some of the more common features are flattened facial features, small head, short neck, protruding tongue, upward slanting eyes, unusual for the child's ethnic group and unusually shaped ears. Children with Down syndrome may also have poor muscle tone, broad, short hands with a single crease in the palm, relatively short fingers and excessive flexibility.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Down Syndrome - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Down Syndrome (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Down Syndrome (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Down Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 3, 8, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 2 molecules, respectively.

    Down Syndrome (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Report Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Down Syndrome (Genetic Disorders).
    - The pipeline guide reviews pipeline therapeutics for Down Syndrome (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Down Syndrome (Genetic Disorders) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Down Syndrome (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Down Syndrome (Genetic Disorders)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Down Syndrome (Genetic Disorders).
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Down Syndrome (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Down Syndrome - Overview
    Down Syndrome - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Down Syndrome - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Down Syndrome - Companies Involved in Therapeutics Development
    AC Immune SA
    Aelis Farma SAS
    Cortice Biosciences Inc
    Eisai Co Ltd
    ManRos Therapeutics
    NeuroNascent Inc
    OPKO Health Inc
    Down Syndrome - Drug Profiles
    ACI-24 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ALZ-801 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    APH-1104 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    D-217 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    donepezil hydrochloride - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Dosmir - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ELND-005 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    minocycline hydrochloride - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NNI-351 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NNI-362 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    pentylenetetrazol - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Antagonize CB1R for Fragile X Syndrome and Down Syndrome - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to inhibit DYRK1A for Alzheimer's and Down Syndrome - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Inhibit DYRK1A for Alzheimer’s Disease and Down Syndrome - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules for Down Syndrome - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit Dyrk1a for Alzheimer's Disease and Down syndrome - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit DYRK1A for Alzheimer’s Disease and Down Syndrome - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit OLIG2 for Down Syndrome - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Stem Cell Therapy to Activate ZSCAN4 for Down Syndrome, Dyskeratosis Congenita and Edwards Syndrome - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    xamoterol fumarate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Down Syndrome - Discontinued Products
    Down Syndrome - Product Development Milestones
    Featured News & Press Releases
    Apr 05, 2016: AC Immune Announces Publication of Ground-breaking Scientific Publication on anti-Abeta Vaccine in Preclinical Model of Down Syndrome
    Aug 31, 2015: New Down syndrome therapy discovered
    Feb 05, 2015: Neuronascent Announces Expanded Patent Coverage in Russia for Its Down Syndrome Therapeutics
    Nov 20, 2014: Transition Therapeutics Announces Results from ELND005 Clinical Study in Adults with Down Syndrome
    Apr 07, 2014: Transition Therapeutics Announces Development Update
    Sep 04, 2013: Transition Therapeutics Announces Dosing of the First Patient in Phase 2a Study of ELND005 in Down Syndrome
    Sep 03, 2013: Elan Announces Dosing of First Patient in Phase 2a Trial of ELND005 (Scyllo-inositol) in Down Syndrome
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Down Syndrome, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Down Syndrome - Pipeline by AC Immune SA, H1 2017
    Down Syndrome - Pipeline by Aelis Farma SAS, H1 2017
    Down Syndrome - Pipeline by Cortice Biosciences Inc, H1 2017
    Down Syndrome - Pipeline by Eisai Co Ltd, H1 2017
    Down Syndrome - Pipeline by ManRos Therapeutics, H1 2017
    Down Syndrome - Pipeline by NeuroNascent Inc, H1 2017
    Down Syndrome - Pipeline by OPKO Health Inc, H1 2017
    Down Syndrome - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Down Syndrome, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    AC Immune SA
    Aelis Farma SAS
    Cortice Biosciences Inc
    Eisai Co Ltd
    ManRos Therapeutics
    NeuroNascent Inc
    OPKO Health Inc

    Request for Sample

    Report Url http://www.reportsweb.com//down-syndrome-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//down-syndrome-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//down-syndrome-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments